Johnson & Johnson Shots to Stay Scarce in U.S. Until Plant Is Approved, White House Official Says Johnson & Johnson will allocate 86 percent fewer doses across the United States next week than are currently being allocated, according to C.D.C. A White House official warned that Johnson & Johnson Covid vaccines will be scarce until a troubled plant gains regulatory approval. But increases from Moderna and Pfizer will not make up for the plunge in Johnson & Johnson supply. Johnson & Johnson was a latecomer to winning federal authorization for emergency use, after Pfizer and Moderna. Tomorrow it could be another section of our country.” The drop-off in Johnson & Johnson doses is directly tied to quality-control issues at the 112,000-square foot plant in southeast Baltimore, run by Emergent BioSolutions, a subcontractor to Johnson & Johnson.

Source: International New York Times April 09, 2021 09:04 UTC